Japan Womens Healthcare Market

ID: MRFR/HC/43461-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Japan Women's Healthcare Market Research Report: Size, Share, Trend Analysis By Indication (Postmenopausal Osteoporosis, Infertility, Reproductive Health Management, Polycystic Ovary Syndrome, Gynecologic Cancer, Others), By Diagnosis (Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing, Others), By Treatment (Therapeutics, Surgeries, Others) and By End Users (Hospitals Clinics, Gynecology Centers, Research Institutes, Others) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Healthcare Services (USD Billion)
      1. 4.1.1 Preventive Care
      2. 4.1.2 Reproductive Health
      3. 4.1.3 Mental Health
      4. 4.1.4 Chronic Disease Management
    2. 4.2 Healthcare, BY Medical Devices (USD Billion)
      1. 4.2.1 Diagnostic Equipment
      2. 4.2.2 Surgical Instruments
      3. 4.2.3 Monitoring Devices
      4. 4.2.4 Therapeutic Devices
    3. 4.3 Healthcare, BY Pharmaceuticals (USD Billion)
      1. 4.3.1 Hormonal Therapies
      2. 4.3.2 Antibiotics
      3. 4.3.3 Pain Management Medications
      4. 4.3.4 Vaccines
    4. 4.4 Healthcare, BY Health Insurance (USD Billion)
      1. 4.4.1 Public Health Insurance
      2. 4.4.2 Private Health Insurance
      3. 4.4.3 Supplemental Health Insurance
    5. 4.5 Healthcare, BY Wellness Programs (USD Billion)
      1. 4.5.1 Nutrition Counseling
      2. 4.5.2 Fitness Programs
      3. 4.5.3 Stress Management
      4. 4.5.4 Health Education
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Astellas Pharma Inc (JP)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Mitsubishi Tanabe Pharma Corporation (JP)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eisai Co Ltd (JP)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Daiichi Sankyo Company Limited (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Otsuka Pharmaceutical Co Ltd (JP)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Chugai Pharmaceutical Co Ltd (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Kyowa Kirin Co Ltd (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 JAPAN MARKET ANALYSIS BY HEALTHCARE SERVICES
    3. 6.3 JAPAN MARKET ANALYSIS BY MEDICAL DEVICES
    4. 6.4 JAPAN MARKET ANALYSIS BY PHARMACEUTICALS
    5. 6.5 JAPAN MARKET ANALYSIS BY HEALTH INSURANCE
    6. 6.6 JAPAN MARKET ANALYSIS BY WELLNESS PROGRAMS
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY HEALTHCARE SERVICES, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY HEALTHCARE SERVICES, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY MEDICAL DEVICES, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY MEDICAL DEVICES, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY PHARMACEUTICALS, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY PHARMACEUTICALS, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY HEALTH INSURANCE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY HEALTH INSURANCE, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY WELLNESS PROGRAMS, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY WELLNESS PROGRAMS, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY HEALTHCARE SERVICES, 2026-2035 (USD Billion)
      2. 7.2.2 BY MEDICAL DEVICES, 2026-2035 (USD Billion)
      3. 7.2.3 BY PHARMACEUTICALS, 2026-2035 (USD Billion)
      4. 7.2.4 BY HEALTH INSURANCE, 2026-2035 (USD Billion)
      5. 7.2.5 BY WELLNESS PROGRAMS, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Japan Japan Womens Japan Womens Healthcare Market Market Segmentation

Japan Womens Healthcare Market By Japan Womens Healthcare Market Services (USD Billion, 2026-2035)

  • Preventive Care
  • Reproductive Health
  • Mental Health
  • Chronic Disease Management

Japan Womens Healthcare Market By Medical Devices (USD Billion, 2026-2035)

  • Diagnostic Equipment
  • Surgical Instruments
  • Monitoring Devices
  • Therapeutic Devices

Japan Womens Healthcare Market By Pharmaceuticals (USD Billion, 2026-2035)

  • Hormonal Therapies
  • Antibiotics
  • Pain Management Medications
  • Vaccines

Japan Womens Healthcare Market By Health Insurance (USD Billion, 2026-2035)

  • Public Health Insurance
  • Private Health Insurance
  • Supplemental Health Insurance

Japan Womens Healthcare Market By Wellness Programs (USD Billion, 2026-2035)

  • Nutrition Counseling
  • Fitness Programs
  • Stress Management
  • Health Education

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035